MENU
+Compare
FATE
Stock ticker: NASDAQ
AS OF
May 19 closing price
Price
$1.22
Change
+$0.15 (+14.02%)
Capitalization
139.85M

FATE Fate Therapeutics Forecast, Technical & Fundamental Analysis

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States... Show more

Industry: #Biotechnology
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for FATE with price predictions
May 16, 2025

FATE sees MACD Histogram just turned negative

FATE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 06, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 60 instances where the indicator turned negative. In of the 60 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for FATE moved out of overbought territory on April 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FATE entered a downward trend on April 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

FATE moved above its 50-day moving average on May 16, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FATE crossed bullishly above the 50-day moving average on April 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.485) is normal, around the industry mean (15.632). P/E Ratio (0.000) is within average values for comparable stocks, (61.690). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.165). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (10.799) is also within normal values, averaging (276.150).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

FATE is expected to report earnings to rise 20.56% to -38 cents per share on July 30

Fate Therapeutics FATE Stock Earnings Reports
Q2'25
Est.
$-0.39
Q1'25
Beat
by $0.07
Q4'24
Est.
$-0.44
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.13
The last earnings report on May 13 showed earnings per share of -31 cents, beating the estimate of -38 cents. With 3.20M shares outstanding, the current market capitalization sits at 139.85M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12278 Scripps Summit Drive
Phone
+1 858 875-1800
Employees
220
Web
https://www.fatetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY594.850.65
+0.11%
SPDR® S&P 500® ETF
BTC.X105606.180000-839.828100
-0.79%
Bitcoin cryptocurrency
AAPL208.78-2.48
-1.17%
Apple
GME27.89-0.56
-1.97%
GameStop Corp
TSLA342.09-7.89
-2.25%
Tesla

FATE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+14.02%
ALLO - FATE
57%
Loosely correlated
-1.80%
NTLA - FATE
56%
Loosely correlated
+6.59%
CRSP - FATE
53%
Loosely correlated
-0.23%
CRBU - FATE
52%
Loosely correlated
+11.89%
CCCC - FATE
51%
Loosely correlated
+11.59%
More